期刊文献+

特立帕肽治疗老年性骨质疏松症的疗效及生活质量改善 被引量:12

Efficacy and Improvement on Quality of Life in Senile Osteoporosis Treated with Teriparatide
下载PDF
导出
摘要 目的研究特立帕肽治疗老年性骨质疏松症患者的骨密度(BMD)和骨标志物的变化,评估生活质量的改善。方法选取老年性骨质疏松症患者45例,给予特立帕肽20μg,每个月注射28 d,疗程12个月。在治疗前和治疗3,6和12个月分别检测BMD,抽血查生化指标和骨标志物;疼痛数字评分法(NRS)进行疼痛评分;采用简明健康状况调查表(SF-36量表)进行生活质量的评定。结果治疗前患者NRS评分为(4.96±2.25)分,治疗3,6及12个月后,患者NRS评分分别为(2.84±1.41),(1.56±1.16),(1.36±1.00)分(P<0.01)。患者治疗后总SF-36评分也较治疗前明显增高(P<0.05)。治疗3,6及12个月,腰椎BMD分别提高约7.7%,12.3%及15.4%;股骨颈BMD提高约3.0%,6.1%及7.6%;股骨粗隆BMD分别提高5.7%,8.6%及10.0%。治疗3,6和12个月后患者血清骨钙素、骨碱性磷酸酶、Ⅰ型前胶原N-端前肽较治疗前均明显增高(P<0.01),而β型胶原交联C端肽在治疗后12个月有明显降低(P<0.05)。治疗期间副作用少。结论特立帕肽治疗老年性骨质疏松1年后可明显减轻骨痛,增加腰椎和股骨粗隆BMD,改善患者生活质量。 Objective To explore the changes of bone mineral density( BMD) and bone markers in senile osteoporosis patients treated with teriparatide,and evaluate the improvement on quality of life( QOL) as well as the clinical significance.Methods Forty-five senile osteoporosis inpatients were treated with 20 μg of teriparatide for one year. BMD and bone markers were detected before treatment and also in the third,sixth and twelfth month during treatment. The level of numerical rating scale( NRS) and QOL were assessed. Results The NRS before treatment was( 4. 96 ± 2. 25),and those after treatment of 3,6and 12 months were( 2. 84 ± 1. 41),( 1. 56 ± 1. 16) and( 1. 36 ± 1. 00),respectively( P 〈0. 01). The total scores of SF-36 significantly increased after treatment( P 〈0. 01). After treatment of 3,6 and 12 months,BMD of lumbar vertebra had increased 7. 7%,12. 3% and 15. 4%,respectively; that of femoral neck had increased 3. 0%,6. 1% and 7. 6%,respectively;and that of intertrochanteric bone had increased 5. 7%,8. 6% and 10. 0%,respectively. Meanwhile,the serum levels of osteocalcin,bone alkaline phosphatase and N terminal propeptide of type I procollagen were significantly higher than those before treatment( P 〈0. 01),nevertheless beta collagen cross-linked C-terminal peptide( β-CTX) only significantly decreased at the12 thmonth after treatment( P〈 0. 05). Conclusion Chronic teriparatide therapy could significantly relieve bone pain,improve the quality of life and increase lumbar vertebra BMD in senile osteoporosis.
出处 《医药导报》 CAS 2017年第6期622-625,共4页 Herald of Medicine
关键词 特立帕肽 骨质疏松症 骨密度 骨标志物 生活质量 Teriparatide Osteoporosis Bone mineral density Bone markers Quality of life
  • 相关文献

参考文献2

二级参考文献7

  • 1赵燕玲,潘子昂,王石麟,王虔,刘京萍,刘忠厚.中国原发性骨质疏松症流行病学[J].中国骨质疏松杂志,1998,4(1):1-4. 被引量:146
  • 2魏雅楠,苗懿德,刘忠厚,刘杰.骨代谢生化标志物的临床进展——不同国家和地区绝经前后女性骨代谢标志物参考值回顾分析[J].中国骨质疏松杂志,2007,13(7):455-468. 被引量:23
  • 3Colleen A McHomey, John E Ware, Anastasia E Raczek. The MOS 36-item short-form health survey(SF-36) :Ⅱ. Psychometric and ellnieal tests of validity in measuring physical and mental health constructs [ J]. Medical Care, 1993,31 (3) :247
  • 4Chesnut CH. Tiludronate : development as an osteoporosis therapy[ J ]. Bone, 1995,17(5 Suppl) :517 - 519
  • 5Josse RG. Prevention and management of osteoporosis : consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women[J]. Can Med Assoc J, 1996,155(7) :929 - 934
  • 6Johnell O. Advances in osteporosis:better identification of risk factors can reduce morbidity and mortality[ J]. J Intern Med, 1996,239 (4) : 299 - 304
  • 7Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada[ J]. Can Med Assoc J, 1996,155(8) : 1113 - 1133

共引文献18

同被引文献111

引证文献12

二级引证文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部